Evidence map›Paper›PMID 33903744›Full record

ArticleNature biomedical engineering2021

Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets.

Quanyin Hu, Hongjun Li, Edikan Archibong, Qian Chen, Huitong Ruan, Sarah Ahn, Elena Dukhovlinova, Yang Kang, Di Wen, Gianpietro Dotti and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature biomedical engineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
159citing papers in PubMed, 2 pooled it
22.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

159 citing papers in PubMed, 2 syntheses or guidelines pooled it, 359 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Engineering platelets as cancer therapeutics.Nature reviews. Clinical oncology · 2026
    Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. National science review · 2026
    Article
  20. Review

99 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Quanyin Hu *Department of Bioengineering, University of California, Los Angeles, CA, USA.
Hongjun Li *Department of Bioengineering, University of California, Los Angeles, CA, USA.
Edikan ArchibongJoint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, USA.ORCID http://orcid.org/0000-0002-1026-1699
Qian ChenDepartment of Bioengineering, University of California, Los Angeles, CA, USA.
Huitong RuanDepartment of Bioengineering, University of California, Los Angeles, CA, USA.
Sarah AhnLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Elena DukhovlinovaLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Yang KangDepartment of Bioengineering, University of California, Los Angeles, CA, USA.
Di WenDepartment of Bioengineering, University of California, Los Angeles, CA, USA.
Gianpietro DottiLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. gdotti@med.unc.edu.ORCID http://orcid.org/0000-0002-2639-8526
Zhen GuDepartment of Bioengineering, University of California, Los Angeles, CA, USA. guzhen@zju.edu.cn.ORCID http://orcid.org/0000-0003-2947-4456
University of North Carolina at Chapel Hill · USCalifornia NanoSystems Institute · USNorth Carolina State University · US

Funding

CAROLINA CANCER NANOTECHNOLOGY TRAINING PROGRAM (C-CNTP)T32CA196589 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Gaorav P. Gupta, ALEXANDER V KABANOV · 2015 to 2026
$4.5M
Platelets-Mediated Delivery of Checkpoint Inhibitors for Post-Surgical Cancer ImmunotherapyR01CA234343 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LI, SONG · 2019 to 2023
$2.0M
Cellular Immunotherapy of Ovarian CancerR01CA243543 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DOTTI, GIANPIETRO · 2019 to 2023
$2.0M
NCI NIH HHS R01 CA234343NCI NIH HHS R01 CA243543NCI NIH HHS T32 CA196589
6 · The paper itself

Abstract

The immunosuppressive microenvironment of solid tumours reduces the antitumour activity of chimeric antigen receptor T cells (CAR-T cells). Here, we show that the release-through the implantation of a hyaluronic acid hydrogel-of CAR-T cells targeting the human chondroitin sulfate proteoglycan 4, polymer nanoparticles encapsulating the cytokine interleukin-15 and platelets conjugated with the checkpoint inhibitor programmed death-ligand 1 into the tumour cavity of mice with a resected subcutaneous melanoma tumour inhibits the local recurrence of the tumour as well as the growth of distant tumours, through the abscopal effect. The hydrogel, which functions as a reservoir, facilitates the enhanced distribution of the CAR-T cells within the surgical bed, and the inflammatory microenvironment triggers platelet activation and the subsequent release of platelet-derived microparticles. The post-surgery local delivery of combination immunotherapy through a biocompatible hydrogel reservoir could represent a translational route for preventing the recurrence of cancers with resectable tumours.

Indexed as

Cell-Derived MicroparticlesImmunotherapy, AdoptiveAnimalsAntibodies, Monoclonal, HumanizedBlood PlateletsHydrogelsMiceNeoplasm Recurrence, LocalT-LymphocytesTumor MicroenvironmentAntibodies, Monoclonal, HumanizedatezolizumabHydrogels

Identifiers

PMID33903744
PMCPMC9102991
OpenAlexW3157425701

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.